The role of CAR-T cells in the immunotherapy of B-cell acute lymphoblastic leukemia: a systematic review
DOI:
https://doi.org/10.33448/rsd-v12i6.42035Keywords:
Acute lymphoblastic leukemia; CAR-T cells; Chimeric antigen receptor; Immunotherapy.Abstract
Introduction: Therapy with CAR-T cells for hematological malignancies, especially B cells, has shown promising results and has become an alternative for the clinical practice of acute lymphoblastic leukemia. Objective: To evaluate the efficacy, safety and applicability of CAR-T cell therapy in the immunotherapy of B-cell acute lymphoblastic leukemia (B-ALL). Methodology: This is a systematic review study guided by the PRISMA method. PubMed and VHL databases were used to search for phase I and II clinical trials, published between 2013 and 2023, with the descriptors “CAR-T cells” or “chimeric antigen receptor” and “immunotherapy” or “treatment”. and “acute lymphoblastic leukemia” and “B cells”. Results: 2,204 reports were identified. Of these, 13 met the eligibility criteria and were included in the study. High response rates have been observed, with complete and morphological remissions ranging from 40-100%. Occurrence of cytokine release syndrome of any degree between 80-85%, severe syndrome of 16-26% and severe neurotoxic effects of 28-42% among patients, although immune-mediated and favorable to the safety of therapy. Conclusion: CAR-T cell immunotherapy demonstrated potent antileukemic activity, with a well-defined toxicity profile and favorable therapy safety, leading to the approval of a CAR-T cell product for the treatment of relapsed/refractory ALL-B.
References
American Cancer Society. (2021). Cancer Facts & Figures, https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures 2021.pdf.
Administração de alimentos e medicamentos dos EUA. (2017). Documento informativo da FDA: Reunião do Comitê Consultivo de Medicamentos Oncológicos; BLA 125646; Tisagenlecleucel, Novartis Pharmaceuticals Corporation, https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM566166.pdf. Acesso em 20/05/2023.
Brentjen, R. J., Davila, M. L., Riviere, I., Park, J., et al. (2013). As células T direcionadas para CD19 induzem rapidamente remissões moleculares em adultos com leucemia linfoblástica aguda refratária à quimioterapia. Science Translational Medicine, 5177.
Brudno, J. N., & Kochenderfer, J. N. (2016). Toxicidades de células T receptoras de antígenos quiméricos: reconhecimento e manejo. Sangue, 26(127), 30-3321.
Davila, M.L., Rivière, I., Wang, X. et al. (2014). Gerenciamento de eficácia e toxicidade da terapia com células T CAR 19-28z na leucemia linfoblástica aguda de células B. Science Translational Medicine, 6(224), 25-224.
.
Denyer, D, &Tranfield, D. (2006). Using qualitative research synthesis to build an actionable knowledge base. Management Decision, 44,213-227. DOI: 10,1108 / 00251740610650201.
Gill, S., & Junho, C. H. (2015). Tornando-se viral: Terapia com células T do receptor de antígeno quimérico para malignidades hematológicas. Immunological Reviews, 1(263), 68-89.
Grupp, S.A., Kalos, M., Barrett, D. et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. New England of Journal Medicine, 16(386), 1509-1518.
Gust, J., Hay, K.A., Hanafi, L.A. et al. (2017). Ativação Endotelial e Ruptura da Barreira Hematoencefálica na Neurotoxicidade após Imunoterapia Adotiva com Células CAR-T CD19. Câncer Discovery, 7(12), 1404-1419.
Hazin, I., Garcia, D., Gomes, E., Leite, D., Balaban, B., Guerra, A. et al. (2015). Desempenho intelectual pós tratamento de câncer: um estudo com crianças. Psicologia: Reflexão e Crítica, 3(28), 565-73.
Hofbrand, A.V., & Moss, P.A.H. (2013). Fundamentos em Hematologia. (6a ed.), Artmed, 454.
Houot, R., Schultz, L.M., Marabelle, A., & Kohrt, H. (2015). T-cell-based immunotherapy: adoptive cell transfer and checkpoint inhibition. Cancer Immunol Research, 3(10), 1115-22.
Instituto Nacional De Câncer José Alencar Gomes da Silva (INCA). (2019). Estimativa 2020: Incidência de Câncer no Brasil. Rio de Janeiro. INCA, https://www.inca.gov.br/publicacoes/livros/estimativa-2020-incidencia-de-cancer-no-brasil.
Inaba, H., Greaves, M., & Mullighan, C.G. (2013). Acute lymphoblastic leukaemia. Lancet, 381(9881), 1943-55.
Kaatsch, P. (2010). Epidemiology of childhood cancer. Cancer Treatment Reviews 4(36), 277-85.
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A. et al. (2012). Depleção de células B e remissões de malignidade juntamente com toxicidade associada a citocinas em um ensaio clínico de células T transduzidas por receptor de antígeno quimérico anti-CD19. Sangue, 119, 2709-2720.
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M. et al. (2015). Células T expressando receptores de antígeno quimérico CD19 para leucemia linfoblástica aguda em crianças e adultos jovens: um estudo de fase 1 de aumento de dose. Lancet, 385(9967), 517-528.
Majhail, N. S., Mau, L. W., Denzen, E. M., Arneson, T. J. (2013). Custos do transplante autólogo e alogênico de células hematopoéticas nos Estados Unidos: um estudo utilizando um grande banco de dados privado de sinistros. Transplante de Medula Óssea, 2(48), 294–300.
Maude, S. L., Laetsch, T. W., Buechner, J. et al. (2018). Tisagenlecleucel em crianças e adultos jovens com leucemia linfoblástica de células B. New England Journal of Medicine, 5(378), 4-439.
Maude, S. L., Frey, N., Shaw, P. A. et al. (2014). Células T do receptor de antígeno quimérico para remissões sustentadas na leucemia. New England Journal of Medicine, 16(371), 1507-1517.
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., et al. (2017). Axicabtagene ciloleucel CAR terapia de células T em linfoma refratário de grandes células B, 26(377), 2531-2544.
Prasad, V. (2018). Imunoterapia: Tisagenlecleucel – a primeira terapia de células CAR-T aprovada: implicações para pagadores e formuladores de políticas. Nat Rev Clin Oncol, 1(15), 11-12.
Riddell, S. R., Maloney, D. G., & Turtle, C. J. (2017). Ativação Endotelial e Ruptura da Barreira Hematoencefálica na Neurotoxicidade após Imunoterapia
Adotiva com Células CAR-T CD19. Câncer Discovery, 7(12), 1404-1419.
Ruella, M., Kenderian, S. S., Shestova, O., Klichinsky, M., Melenhorst, J. J., Wasik, M. A., et al. (2017). Leucemia, 19(31), 1-246.
Sadelain, M., Brentjens, R., & Rivière, I. (2013). Os princípios básicos do design do receptor de antígeno quimérico. Câncer Descoberta, 3, 388-398.
Salim, N., Rahman, M. N. A., & Wahab, D. A. (2019) A systematic literature review of internal capabilities for enhancing eco-innovation performance ofmanufacturing firms. Journal of Cleaner Production, 209, 1445-1460. https://doi.org/10.1016/j.jclepro.2018.11.105
Scheurer, M. E., & Spector, L. G. (2018). Epidemiologia do Câncer Infantil. Pediatria de Rudolph. 26. Ed: Colina McGraw, https://accesspediatrics.mhmedical.com/content.aspx?bookid=2126§ionid=172502659
Tranfield, D., Denyer, D., & Smart, P. (2003). Towards a methodology for developing evidence-informed management knowledge by means of systematic review. British Journal Management, 14,207-222. https://doi.org/10.1111/1467-8551.00375
Turtle, C. J., Hanafi, L. A., Berger, C. et al. (2016). Células CD19 CAR-T de CD4(+): composição CD8(+) definida em pacientes adultos com LLA de células B. Journal of Clinical Investigation, 6(126), 12123-2138.
Zhao, Z., Chen, Y., Francisco, N. M., Zhang, Y., Wu, M. (2018). The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharmaceutica Sinica B, 4(8), 539-51.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Ágata Samy Ribeiro Carvalho; Andria Mendonça de Souza; Ilder Breno dos Santos Silva; Jessica Janaina Oliveira de Medeiros; Anne Cristine Gomes de Almeida
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
